Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy

Key Points

• To investigate how the diagnosis-to-treatment interval influences outcomes in follicular lymphoma patients treated with immunochemotherapy.
• Utilized international discovery and validation cohorts for analysis.
• Assessed the impact of the diagnosis-to-treatment interval on patient outcomes.
• Compared effects against established prognostic indices.
• Shorter diagnosis-to-treatment intervals were linked to worse patient outcomes.
• The prognostic value of the interval was significant beyond other known indices.
• Implications were noted for risk stratification and clinical trial design.